STAT Plus: Cepheid is accused of overcharging and undersupplying its Covid-19 test to poor countries
As controversy rises over equal access to Covid-19 medical products, a manufacturer of rapid, point-of…
Category: STAT Plus
STAT Plus: Lawmakers urge federal watchdog to probe government’s role in discovering remdesivir
Amid concerns over access to medicines that were hatched with U.S. taxpayer funds, Democratic lawmakers…
STAT Plus: Pharmalittle: Pharma execs nix meeting with Trump; Kodak wins big U.S. loan to fix medical supply chain
Hello, everyone, and how are you today? We are doing reasonably well, given the circumstances….
STAT Plus: New York panel seeks extra Medicaid rebates from Biogen for pricey rare disease drug
A New York State panel has recommended that officials seek a supplemental Medicaid rebate for…
STAT Plus: Generic group fails again to block California law that bans pay-to-delay deals
A federal appeals court denied a bid by a pharmaceutical industry trade group to block…
.jpg)
STAT Plus: Pharmalittle: Moderna gets $472 million as late-stage Covid-19 vaccine trial begins; EU turns away from WHO vaccine effort
Good morning, everyone, and nice to see you again. We have returned, so to speak,…
STAT Plus: Pharmalittle: Moderna loses a key patent decision; China says its Covid-19 vaccine will be ready this year
Good morning and happy Friday. Elizabeth Cooney here, thinking of the vacationing Ed Silverman’s weekly…
STAT Plus: A test you can breathe in: Scientists are developing synthetic biosensors to monitor lung disease
Imagine inhaling a sensor that could monitor lung disease patients’ response to therapy, emitting a…
STAT Plus: New research finds a wide gulf in engagement with digital mental health tools
A first-of-its-kind analysis, conducted in collaboration with researchers at Microsoft, paints a detailed picture of…
STAT Plus: Ruling threatens to upend patents on Moderna’s Covid-19 vaccine
Moderna, racing to develop a vaccine for Covid-19, lost a key patent decision Thursday, one…
STAT Plus: The FDA got a lot more flexible during Covid — and pharma’s already pushing to make it permanent
WASHINGTON — The pharmaceutical industry made it clear to the Food and Drug Administration that…
STAT Plus: ‘Inactive’ drug ingredients are not always inactive, study finds
What’s in that pill you just swallowed? The label on the bottle lists the drug’s…
STAT Plus: Pharmalittle: NIH launching ‘flurry’ of Covid-19 treatment trials; Pfizer-BioNTech deal sets ceiling for vaccine price
Good morning. Elizabeth Cooney here, filling in for Ed Silverman until he returns from vacation…
STAT Plus: Eyeing an IPO, Hims expands further into virtual mental health care
San Francisco startup Hims & Hers took a further step into the mental health realm…
STAT Plus: Health tech companies are shelling out more to lobby Washington during the pandemic
In the first half of 2020, the pandemic spurred a surge in the use of…
STAT Plus: Pharmalittle: U.S. to pay $1.95b for Pfizer-BioNTech Covid-19 vaccine; who decides who gets the first doses?
Good morning. Elizabeth Cooney here, channeling the vacationing Ed Silverman’s Wednesday wisdom: We’ve made it…
STAT Plus: Among biotech venture capital firms, Flagship Pioneering got the best single-fund returns
A fund launched in 2012 by the biotech venture capital firm Flagship Pioneering is on…
STAT Plus: Hospitals deploy AI to send patients home earlier — and keep them there
Beth Israel Deaconess Medical Center has a problem familiar to many hospitals: Too many patients…
STAT Plus: In unusual arrangement, deputy HHS secretary’s wife has been lobbying the agency on behalf of health care companies
WASHINGTON — Emily Hargan, who is married to Department of Health and Human Services Deputy…
STAT Plus: As new users flock to health apps, experts raise questions about public understanding of data privacy
As digital health tools proliferate, health data experts are raising a new round of alarms…
STAT Plus: Pharmalittle: Covid-19 vaccines may need two doses; lawmakers grilling pharma execs own their stocks
Good morning. Elizabeth Cooney here again, subbing for the vacationing Ed Silverman as the week…
STAT Plus: CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study
CytoDyn released safety data on its experimental drug for Covid-19 on Tuesday, but efficacy data…
STAT Plus: Cancer startup aims precision medicine at rare genetic driver
A company focused on developing precision medicines to treat patients whose cancers are driven by…
STAT Plus: Many drug companies working on Covid-19 vaccines and treatments are lobbying harder than usual
WASHINGTON — Pharmaceutical companies racing to develop coronavirus treatments and vaccines have upped their lobbying…
STAT Plus: FDA extends deadline for stem cell clinics to comply with drug development rules
The Food and Drug Administration has pushed back by six months the deadline by which…
STAT Plus: Three lawmakers own large sums of stock in vaccine makers set to testify before their committee
Three of the lawmakers tasked with grilling pharmaceutical executives on the development of Covid-19 vaccines…
STAT Plus: Pharmalittle: U.K. inks coronavirus vaccine deal; Synairgen says its drug lowers Covid-19 risk
Good morning. Elizabeth Cooney here in Boston, sitting in for Ed Silverman, who’s on holiday…
STAT Plus: Pharmalittle: Hydroxychloroquine fails once more; Russian hackers target coronavirus vaccine data
Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the…
STAT Plus: Corbus Pharma is nearing the readout of a pivotal drug study. Here’s what you need to know
Four years ago, Corbus Pharmaceuticals claimed success in a mid-stage clinical trial of its lead…
STAT Plus: Startup Spotlight: Glympse Bio hopes its test will show whether drugs are actually working
Cambridge, Mass.-based startup Glympse Bio has raised more than $45 million for its nanoparticle-based biosensors,…
STAT Plus: Operation Warp Speed doesn’t have the transparency it needs
So much for transparency. In what can only be called a disappointing decision, the Trump…
STAT Plus: As Amazon builds new health ventures, Haven struggles to gain ground
Amazon’s sprawling, sometimes stilted approach to employee health care is growing more complicated — and…
STAT Plus: Novartis to provide drugs for Covid-19 patients at no cost, but fails to disclose pricing
As companies face pressure to ensure access to medicines during the pandemic, Novartis (NVS) plans…
STAT Plus: Pharmalittle: Warp Speed chief can avoid ethics disclosures; China OKs a BioNTech Covid-19 vaccine trial
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT Plus: The founder of Adimab believes he can combat Covid-19 — and whatever pandemic comes next
One of biotech’s most respected entrepreneurs is betting the novel coronavirus won’t be the last…
STAT Plus: House Democrats are using the budget process to slam the Trump administration’s Covid-19 response
A version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the…
STAT Plus: Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response
Buoyed by newly published, early data on its experimental Covid-19 vaccine, Moderna on Wednesday cracked…
STAT Plus: Pharmalittle: Moderna vaccine is a ‘good beginning’; hospitals stock up on drugs for Covid-19
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: AbbVie uses dozens of patents to ward off competition for a pricey cancer medicine
The pricey Imbruvica cancer treatment that became available seven years ago could have its monopoly…
STAT Plus: Drug maker offers to slash prices on cancer medicines to end European price gouging probe
In response to a probe into alleged price gouging, Aspen Pharma has agreed to slash…
STAT Plus: Sun Pharma employee says she was fired for complaining that samples were improperly shipped
A former Sun Pharmaceutical sales rep filed a lawsuit arguing she was fired from her…
STAT Plus: Seeking EU approval on acquisition, Google pledges not to use Fitbit health data to target ads
With the clock ticking on a European Commission probe into Google’s $2.1 billion bid for…
STAT Plus: Ohio sues Express Scripts for ‘egregiously’ overcharging for medicines
The Ohio Attorney General has filed a lawsuit alleging Express Scripts overcharged a state pension…
STAT Plus: Pharmalittle: Pharma ramps up clinical trials after Covid-19 delays; skepticism high over vaccine profits and global distribution
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT Plus: Blueprint Medicines partners with Roche to develop and sell genetically targeted cancer drug
Blueprint Medicines is partnering with Roche to develop and market a cancer drug near approval…
STAT Plus: Sanofi and MD Anderson team up to accelerate cancer drug testing
In another sign of its renewed emphasis on cancer, Sanofi (SNY) said Tuesday it will…
STAT Plus: European Parliament backs WHO effort to create a Covid-19 technology access pool
In an overwhelming vote, the European Parliament late last week voted to support a World…
STAT Plus: Pharma trade group scolds Gilead again for misleading information about a rival HIV drug
For the second time in less than two years, Gilead Sciences (GILD) has been reprimanded…
STAT Plus: Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic
One week after the New York City drug developer Applied Therapeutics announced it was working…
STAT Plus: Pharmalittle: FDA fast-tracks two BioNTech and Pfizer vaccines; U.S. hospitals running short of remdesivir
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…